Device-Aided Therapies in Parkinson's Disease-Results from the German Care4PD Study

Odette Fruendt, Anne-Marie Hanff, Annika Moehl, Tobias Mai, Christiane Kirchner, Ali Amouzandeh, Carsten Buhmann, Rejko Kruger, Martin Suedmeyer*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Data on the use of device-aided therapies (DATs) in people with Parkinson's disease (PwP) are scarce. Analyzing data from the Care4PD patient survey, we (1) evaluated application frequency and type of DAT in a larger, nationwide, cross-sectoral PwP sample in Germany; (2) analyzed the frequency of symptoms indicative for advanced PD (aPD) and need for DAT amongst the remaining patients and (3) compared the most bothersome symptoms and need for professional long-term care (LTC) of patients with and without suspected aPD. Data from 1269 PwP were analyzed. In total, 153 PwP (12%) received DAT, mainly deep brain stimulation (DBS). Of the remaining 1116 PwP without DAT, >50% fulfilled at least one aPD criterion. Akinesia/rigidity and autonomic problems were most bothersome for PwP with and without suspected aPD, with more tremor in the non-aPD and more motor fluctuations and falls in the aPD group. To recapitulate, the German DAT application rate is rather low, although a large proportion of PwP fulfills aPD criteria indicating a need for intensified treatment strategies. Many reported bothersome symptoms could be overcome with DAT with benefits even for LTC patients. Thus, precise and early identification of aPD symptoms (and therapy-resistant tremor) should be implemented in future DAT preselection tools and educational trainings.
Original languageEnglish
Article number736
Number of pages12
JournalBrain Sciences
Volume13
Issue number5
DOIs
Publication statusPublished - 28 Apr 2023

Keywords

  • Parkinson's disease
  • device-aided therapies
  • deep brain stimulation
  • medication pump
  • infusion therapies
  • advanced
  • disease progression
  • DEEP-BRAIN-STIMULATION
  • CARBIDOPA INTESTINAL GEL
  • AUTONOMIC DYSFUNCTION
  • COST-EFFECTIVENESS
  • APOMORPHINE
  • LEVODOPA
  • NEUROSTIMULATION

Cite this